← All trials
NCT04478448
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 13, 2020
- Primary completion
- Aug 20, 2020
- Completion date
- Aug 26, 2020
- First posted
- Jul 20, 2020
- Last posted
- Sep 2, 2020
- Enrollment
- 26
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Genuine Research Center, EgyptLead sponsor
- Genuine Research Center, EgyptStudy director
- European Egyptian Pharmaceutical IndustriesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.